The prevention of cognitive decline and dementia is a major public health priority. The Memory and Aging Project (MAP) has made considerable progress elucidating the complex relationships between risk factors, common neuropathologies and resilience markers that increase or decrease the rate of cognitive decline, and risk of dementia. In nearly 200 peer-reviewed manuscripts, we reported genetic, medical, experiential, and psychological factors associated with increased or decreased rates of cognitive decline and dementia risk. We reported that Alzheimer's, vascular, and Lewy body pathologies (AD, CVD, LBD) explain about 40% of the variation of cognitive decline, and that resilience markers (e.g., cortical presynaptic proteins and locus coeruleus neurons) were associated with a slower rate of decline accounting for 8% of the variation, and that many risk factors with little direct relation o pathologies or resilience markers accounted for >10% of the variation of decline, controlling for pathologies. Additional factors related to cognitive decline await discovery. The overall goal of the planned continuation of MAP is to discover additional proteins associated with the slope of cognitive decline, after accounting for the effects of common pathologies. We use the term """"""""residual cognitive decline"""""""" to describe this innovative primary study outcome. Methods to interrogate the genome, and therefore, the proteome, have improved markedly over the past decade, making the discovery of proteins that underlie cognitive decline both timely and feasible. We plan to continue collecting clinical and post-mortem data on MAP participants.
Aim 1, Discovery and Verification Phase, will combine """"""""omics-wide"""""""" association studies with innovative integrative pathway analyses on genomic, epigenomic, and transcriptomic data from human brain from 500 MAP participants to discover proteins associated with residual cognitive decline;it will select 200 proteins for quantitation in human brain to verify that protein level i associated with residual cognitive decline.
Aim 2, Validation Phase, will quantify the 200 proteins selected and verified in Aim 1 with a new sample of 350 brains from MAP participants that will accrue by the end the funding period, followed by a joint statistical analysis to increas power (n=850).
Aim 3 will link the validated proteins to the wealth of available risk factor data t discover novel biologic pathways linking risk factors to cognitive decline and dementia. Our plan is supported by extensive and compelling new preliminary data that demonstrate its high likelihood of success and demonstrate that the study is innovative, high yield and low risk. The continuation of MAP will discover additional proteins associated with cognitive decline and novel biologic pathways linking risk factors to cognitive decline. These proteins will represent either unknown pathologies that increase rates of cognitive decline or resilience markers that decrease rates of cognitive decline. Both sets of proteins will offer new therapeutic targets for the prevention and treatment of cognitive decline and dementia. Thus, the study has the potential to have a high and sustained impact on aging and dementia research.

Public Health Relevance

The prevention of cognitive decline, MCI and dementia is a major public health priority. The proposed continuation of MAP will discover additional proteins associated with cognitive decline and novel biologic pathways linking risk factors to cognitive decline, MCI and dementia. These proteins, representing unknown pathologies and resilience markers associated with faster and slower rates of cognitive decline, will offer new therapeutic targets for the prevention and treatment of cognitive decline, MCI and dementia.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Project (R01)
Project #
Application #
Study Section
Neurological, Aging and Musculoskeletal Epidemiology Study Section (NAME)
Program Officer
Anderson, Dallas
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Rush University Medical Center
Schools of Medicine
United States
Zip Code
Chibnik, L B; White, C C; Mukherjee, S et al. (2018) Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies. Mol Psychiatry 23:1521-1529
Li, Peng; Yu, Lei; Lim, Andrew S P et al. (2018) Fractal regulation and incident Alzheimer's disease in elderly individuals. Alzheimers Dement 14:1114-1125
Yu, Lei; Petyuk, Vladislav A; Gaiteri, Chris et al. (2018) Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia. Ann Neurol 84:78-88
Arvanitakis, Zoe; Leurgans, Sue E; Fleischman, Debra A et al. (2018) Memory complaints, dementia, and neuropathology in older blacks and whites. Ann Neurol 83:718-729
Ganguli, Mary; Albanese, Emiliano; Seshadri, Sudha et al. (2018) Population Neuroscience: Dementia Epidemiology Serving Precision Medicine and Population Health. Alzheimer Dis Assoc Disord 32:1-9
Capuano, Ana W; Wilson, Robert S; Leurgans, Sue E et al. (2018) Sigmoidal mixed models for longitudinal data. Stat Methods Med Res 27:863-875
Felsky, Daniel; Patrick, Ellis; Schneider, Julie A et al. (2018) Polygenic analysis of inflammatory disease variants and effects on microglia in the aging brain. Mol Neurodegener 13:38
McAninch, Elizabeth A; Rajan, Kumar B; Evans, Denis A et al. (2018) A Common DIO2 Polymorphism and Alzheimer Disease Dementia in African and European Americans. J Clin Endocrinol Metab 103:1818-1826
Morris, Martha Clare; Wang, Yamin; Barnes, Lisa L et al. (2018) Nutrients and bioactives in green leafy vegetables and cognitive decline: Prospective study. Neurology 90:e214-e222
Canli, Turhan; Yu, Lei; Yu, Xiaoqing et al. (2018) Loneliness 5 years ante-mortem is associated with disease-related differential gene expression in postmortem dorsolateral prefrontal cortex. Transl Psychiatry 8:2

Showing the most recent 10 out of 492 publications